DDInter1581 DDInter981
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Metamfetamine {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Isocarboxazid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Metamfetamine {u} (Compound) resembles {v} (Compound) Phenacemide
Phenacemide {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Lacosamide
Lacosamide {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Phenacemide
Phenacemide {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Metamfetamine
Metamfetamine {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Lacosamide
Lacosamide {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Metamfetamine {u} (Compound) resembles {v} (Compound) Benzyl alcohol
Benzyl alcohol {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vorinostat
Vorinostat {u} (Compound) upregulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Isocarboxazid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Benzyl alcohol
Benzyl alcohol {u} (Compound) resembles {v} (Compound) Isocarboxazid
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Isocarboxazid (Compound)
Repaglinide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Isocarboxazid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Phenacemide (Compound) and Phenacemide (Compound) resembles Isocarboxazid (Compound)
Repaglinide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Lacosamide (Compound) and Lacosamide (Compound) resembles Isocarboxazid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Phenacemide (Compound) and Phenacemide (Compound) resembles Isocarboxazid (Compound)
Repaglinide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Metamfetamine (Compound) and Metamfetamine (Compound) resembles Isocarboxazid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Lacosamide (Compound) and Lacosamide (Compound) resembles Isocarboxazid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Benzyl alcohol (Compound) and Benzyl alcohol (Compound) resembles Isocarboxazid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Vorinostat and Vorinostat (Compound) upregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Isocarboxazid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Benzyl alcohol (Compound) and Benzyl alcohol (Compound) resembles Isocarboxazid (Compound)